Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
3,540.00
+40.00 (1.14%)
At close: Sep 8, 2025
Bukwang Pharmaceutical Revenue
Bukwang Pharmaceutical had revenue of 42.58B KRW in the quarter ending June 30, 2025, with 15.34% growth. This brings the company's revenue in the last twelve months to 179.16B, up 53.68% year-over-year. In the year 2024, Bukwang Pharmaceutical had annual revenue of 160.09B with 27.13% growth.
Revenue (ttm)
179.16B
Revenue Growth
+53.68%
P/S Ratio
1.95
Revenue / Employee
291.32M
Employees
615
Market Cap
350.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 160.09B | 34.16B | 27.13% |
Dec 31, 2023 | 125.93B | -64.98B | -34.04% |
Dec 31, 2022 | 190.91B | 8.42B | 4.61% |
Dec 31, 2021 | 182.49B | 12.83B | 7.56% |
Dec 31, 2020 | 169.66B | 1.47B | 0.87% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |